Search ↗

Comparison

CJC-1295 vs Mod GRF 1-29

Both are GHRH analogs, so the meaningful differences are in kinetics, evidence and regulatory status.

CJC-1295 Mod GRF 1-29
Class GHRH analogs GHRH analogs
Evidence Preliminary human Preliminary human
Human trials ~4 ~4
Half-life ~30 minutes ~30 minutes
Reported range 100-300 mcg 100-300 mcg
Frequency 1-2x daily, commonly stacked with a GHRP 1-3x daily
Routes Subcutaneous Subcutaneous
FDA approved No No
Research use only Yes Yes
Banned in sport Yes Yes
Studied for Growth hormone elevation, Body composition, Recovery, Sleep quality Growth hormone elevation, Stacking with GHRPs
Reported side effects Injection-site reactions, Flushing, Water retention, Transient headache, Tingling in extremities Injection-site reactions, Flushing, Water retention

CJC-1295

CJC-1295 without DAC substitutes four amino acids in the GHRH(1-29) backbone, most importantly replacing alanine at position 2 with D-alanine to block dipeptidyl peptidase-4 cleavage. The result is a GHRH receptor agonist with substantially greater metabolic stability than sermorelin but a still-short half-life, which preserves pulsatile release. It is conventionally combined with a GHRP because the two act on separate receptors and produce a greater combined GH pulse than either alone.

Mod GRF 1-29

Mod GRF 1-29 and CJC-1295 without DAC refer to the same tetrasubstituted GHRH(1-29) sequence. The duplicate naming arose from research-chemical labelling rather than from any pharmacological difference, and it is the most common reason buyers receive a product with different kinetics than they intended. The practical risk is confusing this short-acting peptide with the DAC-bound version, whose dosing is an order of magnitude different and weekly rather than daily.

CJC-1295 vs Mod GRF 1-29: common questions

What is the difference between CJC-1295 and Mod GRF 1-29?

Both are GHRH analogs. CJC-1295: A tetrasubstituted GHRH(1-29) analog engineered for protease resistance, most often paired with a ghrelin mimetic. Mod GRF 1-29: A naming convention for the non-DAC tetrasubstituted GHRH(1-29) analog, used interchangeably with CJC-1295 without DAC and a frequent source of dosing confusion.

Which has stronger evidence, CJC-1295 or Mod GRF 1-29?

They sit at the same evidence level: preliminary human. CJC-1295 has about 4 human studies and Mod GRF 1-29 about 4.

Are CJC-1295 and Mod GRF 1-29 FDA approved?

Neither is FDA approved for any indication.

References

Regulatory and primary sources

  1. PubChem compound record (CID 91971820) ↗ · structure, identifiers, synonyms
  2. WADA Prohibited List ↗ · current year
  3. FDA: Unapproved drugs and "research use only" products ↗ · regulatory status of non-approved products
  4. CAS Registry Number 863288-34-0 ↗ · chemical identity

Published literature

  1. Teichman SL, Neale A, Lawrence B, et al.. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.J Clin Endocrinol Metab 2006.PubMed 16352683 · doi:10.1210/jc.2005-1536
  2. Mayfield CK, Bolia IK, Feingold CL, et al.. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.Am J Sports Med 2026.PubMed 41476424 · doi:10.1177/03635465251357593
  3. Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.J Am Acad Orthop Surg Glob Res Rev 2026.PubMed 41490200 · doi:10.5435/JAAOSGlobal-D-25-00236
  4. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.Sports Med 2026.PubMed 41966639 · doi:10.1007/s40279-026-02437-0
  5. Renke G, Chinellato L. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.Int J Mol Sci 2026.PubMed 42123471 · doi:10.3390/ijms27093890
  6. Coutinho LFD, DE Oliveira Neves LF, Camilo RP. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.J Sports Med Phys Fitness 2026.PubMed 41880199 · doi:10.23736/S0022-4707.26.17773-1
  7. Van Hout MC, Hearne E. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.Subst Use Misuse 2016.PubMed 26771670 · doi:10.3109/10826084.2015.1082595
  8. Thomas A, Schänzer W, Delahaut P, et al.. Immunoaffinity purification of peptide hormones prior to liquid chromatography-mass spectrometry in doping controls.Methods 2012.PubMed 21871962 · doi:10.1016/j.ymeth.2011.08.009

Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.

Read this first This page compares published reference data. It is not medical advice and not a recommendation to use either compound. Several compounds documented on this site are not approved for human use.